The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia
Open accessAbstract
A window of opportunity for immune responses to extinguish human immunodeficiency virus type 1 (HIV-1) exists from the moment of transmission through establishment of the latent pool of HIV-1-infected cells. A critical time to study the initial immune responses to the transmitted/founder virus is the eclipse phase of HIV-1 infection (time from transmission to the first appearance of plasma virus), but, to date, this period has been logistically difficult to analyze. To probe B-cell responses immediately following HIV-1 transmission, we have determined envelope-specific antibody responses to autologous and consensus Envs in plasma donors from the United States for whom frequent plasma samples were available at time points immediately before, during, and after HIV-1 plasma viral load (VL) ramp-up in acute infection, and we have modeled the antibody effect on the kinetics of plasma viremia. The first detectable B-cell response was in the form of immune complexes 8 days after plasma virus detection, whereas the first free plasma anti-HIV-1 antibody was to gp41 and appeared 13 days after the appearance of plasma virus. In contrast, envelope gp120-specific antibodies were delayed an additional 14 days. Mathematical modeling of the earliest viral dynamics was performed to determine the impact of antibody on HIV replication in vivo as assessed by plasma VL. Including the initial anti-gp41 immunoglobulin G (IgG), IgM, or both responses in the model did not significantly impact the early dynamics of plasma VL. These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
A Direct Approach to False Discovery Rates
Storey, J. D. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00346 · Cited by 5,603
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Antibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Self-citationKeele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
Self-citationBrenchley, J. M., Schacker, T. W., Ruff, L. E., Price, D. A., Taylor, J. H., Beilman, G. J., Nguyen, P. L., Khoruts, A., Larson, M., Haase, A. T., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040874 · Cited by 1,832
Lane, H. C., Masur, H., Edgar, L. C., Whalen, G., Rook, A. H., & Fauci, A. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308253090803 · Cited by 1,600
Fiebig, E. W., Wright, D. J., Rawal, B. D., Garrett, P. E., Schumacher, R. T., Peddada, L., Heldebrant, C., Smith, R., Conrad, A., Kleinman, S. H., et al. (2003) · AIDS · doi:10.1097/00002030-200309050-00005 · Cited by 1,305
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
Richman, D. D., Wrin, T., Little, S. J., & Petropoulos, C. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630530100 · Cited by 1,200
Nonparametric Regression and Generalized Linear Models: A Roughness Penalty Approach.
Best, D. J., Green, P. J., & Silverman, B. W. (1994) · Biometrics · doi:10.2307/2533467 · Cited by 1,177
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Self-citationFc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Self-citationChun, T.-W., Engel, D., Berrey, M. M., Shea, T., Corey, L., & Fauci, A. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8869 · Cited by 846
Daar, E. S., Moudgil, T., Meyer, R. D., & Ho, D. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104043241405 · Cited by 838
Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4009-4018.1999 · Cited by 783
ACUTE AIDS RETROVIRUS INFECTION
Cooper, D., Maclean, P., Finlayson, R., Michelmore, H., Gold, J., Donovan, B., Barnes, T., Brooke, P., & Penny, R. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91205-x · Cited by 709
Clinical and epidemiologic features of primary HIV infection.
Schacker, T., Collier, A. C., Hughes, J., Shea, T., & Corey, L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-4-199608150-00001 · Cited by 703 · cited 2×
“Given that a narrow window of time might exist for antibodies to be protective and given that immune complexes only arise 18 days after transmission (8 days after T0 with an estimate of time from transmission to T0 of a mean of 10 days; range, 7 to 21 days) (7, 11, 14, 21, 40, 52), then the first antibody response to…”
BackgroundHigh Titers of Cytopathic Virus in Plasma of Patients with Symptomatic Primary HIV-1 Infection
Clark, S. J., Saag, M. S., Decker, W. D., Campbell-Hill, S., Roberson, J. L., Veldkamp, P. J., Kappes, J. C., Hahn, B. H., & Shaw, G. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104043241404 · Cited by 689
Self-citationDendritic-cell interactions with HIV: infection and viral dissemination
Wu, L., & KewalRamani, V. N. (2006) · Nature Reviews Immunology · doi:10.1038/nri1960 · Cited by 574
Modeling Plasma Virus Concentration during Primary HIV Infection
STAFFORD, M. A., COREY, L., CAO, Y., DAAR, E. S., HO, D. D., & PERELSON, A. S. (2000) · Journal of Theoretical Biology · doi:10.1006/jtbi.2000.1076 · Cited by 487
Self-citationRheumatoid Factor Secretion from Human Leu-1 + B Cells
Hardy, R. R., Hayakawa, K., Shimizu, M., Yamasaki, K., & Kishimoto, T. (1987) · Science · doi:10.1126/science.3105057 · Cited by 440
Mascola, J. R., Snyder, S. W., Weislow, O. S., Belay, S. M., Belshe, R. B., Schwartz, D. H., Clements, M. L., Dolin, R., Graham, B. S., Gorse, G. J., et al. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/173.2.340 · Cited by 436
Broad HIV-1 neutralization mediated by CD4-binding site antibodies
Li, Y., Migueles, S. A., Welcher, B., Svehla, K., Phogat, A., Louder, M. K., Wu, X., Shaw, G. M., Connors, M., Wyatt, R. T., et al. (2007) · Nature Medicine · doi:10.1038/nm1624 · Cited by 383
Self-citationPrimary Human T-Lymphotropic Virus Type III Infection
HO, D. D., SARNGADHARAN, M. G., RESNICK, L., DIMARZOVERONESE, F., ROTA, T. R., & HIRSCH, M. S. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-6-880 · Cited by 334
Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection
Gray, E. S., Moore, P. L., Choge, I. A., Decker, J. M., Bibollet-Ruche, F., Li, H., Leseka, N., Treurnicht, F., Mlisana, K., Shaw, G. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00239-07 · Cited by 299
Self-citationAntigenic conservation and immunogenicity of the HIV coreceptor binding site
Decker, J. M., Bibollet-Ruche, F., Wei, X., Wang, S., Levy, D. N., Wang, W., Delaporte, E., Peeters, M., Derdeyn, C. A., Allen, S., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042510 · Cited by 295
Self-citationViral Dynamics of Acute HIV-1 Infection
Little, S. J., McLean, A. R., Spina, C. A., Richman, D. D., & Havlir, D. V. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.6.841 · Cited by 290
Immunoglobulin V H 3 Gene Products: Natural Ligands for HIV gp120
Berberian, L., Goodglick, L., Kipps, T. J., & Braun, J. (1993) · Science · doi:10.1126/science.7690497 · Cited by 263
An HIV Vaccine — Evolving Concepts
Johnston, M. I., & Fauci, A. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra066267 · Cited by 257
Morris, L., Binley, J. M., Clas, B. A., Bonhoeffer, S., Astill, T. P., Kost, R., Hurley, A., Cao, Y., Markowitz, M., Ho, D. D., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.233 · Cited by 254
Self-citationMontero, M., van Houten, N. E., Wang, X., & Scott, J. K. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00020-07 · Cited by 253
Exploiting the defensive sugars of HIV-1 for drug and vaccine design
Scanlan, C. N., Offer, J., Zitzmann, N., & Dwek, R. A. (2007) · Nature · doi:10.1038/nature05818 · Cited by 250
Forthal, D. N., Landucci, G., & Daar, E. S. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6953-6961.2001 · Cited by 220
Self-citationHe, B., Qiao, X., Klasse, P. J., Chiu, A., Chadburn, A., Knowles, D. M., Moore, J. P., & Cerutti, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.3931 · Cited by 218
Moore, J. P., Cao, Y., Ho, D. D., & Koup, R. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.5142-5155.1994 · Cited by 218
Liao, H.-X., Sutherland, L. L., Xia, S.-M., Brock, M. E., Scearce, R. M., Vanleeuwen, S., Alam, S. M., McAdams, M., Weaver, E. A., Camacho, Z. T., et al. (2006) · Virology · doi:10.1016/j.virol.2006.04.043 · Cited by 184
Self-citationThe Rational Design of an AIDS Vaccine
Douek, D. C., Kwong, P. D., & Nabel, G. J. (2006) · Cell · doi:10.1016/j.cell.2006.02.005 · Cited by 166
Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease
Moir, S., & Fauci, A. S. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.04.034 · Cited by 163
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
Haynes, B. F., & Montefiori, D. C. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.3.347 · Cited by 155
Self-citationPrimary HIV-1 infection sets the stage for important B lymphocyte dysfunctions
Titanji, K., Chiodi, F., Bellocco, R., Schepis, D., Osorio, L. M., Tassandin, C., Tambussi, G., Grützmeier, S., Lopalco, L., & Milito, A. D. (2005) · AIDS · doi:10.1097/01.aids.0000191231.54170.89 · Cited by 154
Moore, P. L., Gray, E. S., Choge, I., Ranchobe, N., Mlisana, K. P., Karim, S. S. A., Williamson, C. E., & Morris, L. (2007) · Journal of Virology · doi:10.1128/jvi.02187-07 · Cited by 152
Self-citationHoll, V., Peressin, M., Decoville, T., Schmidt, S., Zolla‐Pazner, S., Aubertin, A.-M., & Moog, C. (2006) · Journal of Virology · doi:10.1128/jvi.02625-05 · Cited by 146
Alam, S. M., Scearce, R. M., Parks, R., Plonk, K., Plonk, S. G., Sutherland, L. L., Górny, M. K., Zolla‐Pazner, S., Vanleeuwen, S., Moody, M. A., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00927-07 · Cited by 120
Self-citationHuber, M., Fischer, M., Misselwitz, B., Manrique, A., Kuster, H., Niederöst, B., Weber, R. K., von Wyl, V., Günthard, H. F., & Trkola, A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030441 · Cited by 113
Mixed models for longitudinal left-censored repeated measures
Thiébaut, R., & Jacqmin‐Gadda, H. (2003) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2003.08.004 · Cited by 111
Gasper-Smith, N., Crossman, D. M., Whitesides, J. F., Mensali, N., Ottinger, J. S., Plonk, S. G., Moody, M. A., Ferrari, G., Weinhold, K. J., Miller, S., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00605-08 · Cited by 104
Self-citationThe Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan
Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020025 · Cited by 72
Phogat, S. K., Svehla, K., Tang, M., Spadaccini, A., Muller, J., Mascola, J. R., Berkower, I. J., & Wyatt, R. T. (2008) · Virology · doi:10.1016/j.virol.2007.11.005 · Cited by 68
Primary HIV-1 Infection Sets the Stage for Important B Lymphocyte Dysfunctions
Titanji, K., Chiodi, F., Bellocco, R., Schepis, D., Cagigi, A., Osorio, L. M., Tassandin, C., Tambussi, G., Grützmeier, S., Lopalco, L., et al. (2005) · Retrovirology · doi:10.1186/1742-4690-2-s1-p95 · Cited by 61
Clutterbuck, E., Salt, P., Oh, S., Marchant, A., Beverley, P. C. L., & Pollard, A. J. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02436.x · Cited by 57
Veazey, R. S., Acierno, P. M., McEvers, K. J., Baumeister, S. H. C., Foster, G., Rett, M. D., Newberg, M. H., Kuroda, M. J., Williams, K. C., Kim, E., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02748-07 · Cited by 39
Self-citationPost-exposure prophylaxis for SIV revisited: animal model for HIV prevention.
Emau, P., Jiang, Y., Agy, M. B., Tian, B., Bekele, G., & Tsai, C. (2006) · AIDS Research and Therapy · doi:10.1186/1742-6405-3-29 · Cited by 25
Cited by
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Self-citationThe immune response during acute HIV-1 infection: clues for vaccine development
McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N., & Haynes, B. F. (2010) · Nature Reviews Immunology · doi:10.1038/nri2674 · Cited by 871
Self-citationStructure and immune recognition of trimeric pre-fusion HIV-1 Env
Pancera, M., Zhou, T., Druz, A., Georgiev, I. S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G.-Y., Ofek, G., et al. (2014) · Nature · doi:10.1038/nature13808 · Cited by 740
Self-citationCohen, M. S., Shaw, G. M., McMichael, A. J., & Haynes, B. F. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011874 · Cited by 660
Self-citationEfficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 598
Self-citation
Metadata
- Authors
- Tomaras, G. D., Yates, N. L., Liu, P., Qin, L., Fouda, G. G., Chavez, L. L., Decamp, A. C., Parks, R. J., Ashley, V. C., Lucas, J. T., Cohen, M., Eron, J., Hicks, C. B., Liao, H.-X., Self, S. G., Landucci, G., Forthal, D. N., Weinhold, K. J., Keele, B. F., Hahn, B. H., Greenberg, M. L., Morris, L., Karim, S. S. A., Blattner, W. A., Montefiori, D. C., Shaw, G. M., Perelson, A. S., & Haynes, B. F.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2008-12-15
- Volume
- 82
- Issue
- 24
- Pages
- 12449-12463
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2108868448
- Cited by
- 631
- References
- 52
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.